Wells Fargo’s SELLAS Life Sciences SLS Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $4.85M | Buy |
328,819
+103,112
| +46% | +$712K | ﹤0.01% | 2873 |
|
|
2026
Q1 | $955K | Sell |
225,707
-73,598
| -25% | -$329K | ﹤0.01% | 3758 |
|
|
2025
Q4 | $1.13M | Buy |
299,305
+223,438
| +295% | +$434K | ﹤0.01% | 3875 |
|
|
2025
Q3 | $122K | Buy |
75,867
+22,052
| +41% | +$39.3K | ﹤0.01% | 5216 |
|
|
2025
Q2 | $118K | Buy |
53,815
+50,812
| +1,692% | +$78K | ﹤0.01% | 5100 |
|
|
2025
Q1 | $3.24K | Buy |
+3,003
| New | +$3.56K | ﹤0.01% | 6093 |
|
|
2024
Q2 | – | Sell |
-301
| Closed | -$304 | – | 7411 |
|
|
2024
Q1 | $304 | Sell |
301
-16,056
| -98% | -$13.5K | ﹤0.01% | 6398 |
|
|
2023
Q4 | $17.3K | Buy |
16,357
+40
| +0.2% | +$43 | ﹤0.01% | 5687 |
|
|
2023
Q3 | $26.8K | Buy |
16,317
+3
| +0% | +$5 | ﹤0.01% | 5478 |
|
|
2023
Q2 | $25.6K | Buy |
16,314
+172
| +1% | +$276 | ﹤0.01% | 5664 |
|
|
2023
Q1 | $23.1K | Buy |
16,142
+2
| +0% | +$5 | ﹤0.01% | 5577 |
|
|
2022
Q4 | $38.1K | Buy |
16,140
+5,004
| +45% | +$14K | ﹤0.01% | 4989 |
|
|
2022
Q3 | $22K | Sell |
11,136
-1
| -0% | -$3 | ﹤0.01% | 5352 |
|
|
2022
Q2 | $25K | Buy |
11,137
+5,039
| +83% | +$14.8K | ﹤0.01% | 5351 |
|
|
2022
Q1 | $41K | Sell |
6,098
-512
| -8% | -$2.99K | ﹤0.01% | 5750 |
|
|
2021
Q4 | $37K | Buy |
6,610
+2,500
| +61% | +$18.9K | ﹤0.01% | 6108 |
|
|
2021
Q3 | $37K | Sell |
4,110
-2,744
| -40% | -$25.5K | ﹤0.01% | 5737 |
|
|
2021
Q2 | $76K | Buy |
6,854
+19
| +0.3% | +$185 | ﹤0.01% | 5399 |
|
|
2021
Q1 | $58K | Buy |
6,835
+6,780
| +12,327% | +$55.5K | ﹤0.01% | 5748 |
|
|
2020
Q4 | $0 | Hold |
55
| – | – | ﹤0.01% | 6963 |
|
|
2020
Q3 | $0 | Buy |
55
+10
| +22% | +$27 | ﹤0.01% | 6839 |
|
|
2020
Q2 | $0 | Buy |
45
+7
| +18% | +$19 | ﹤0.01% | 6761 |
|
|
2020
Q1 | $0 | Buy |
+38
| New | +$98 | ﹤0.01% | 6730 |
|
|
2019
Q4 | – | Sell |
-1
| Closed | – | – | 6695 |
|
|
2019
Q3 | $0 | Hold |
1
| – | – | ﹤0.01% | 6677 |
|
|
2019
Q2 | $0 | Sell |
1
-12
| -92% | -$426 | ﹤0.01% | 6591 |
|
|
2019
Q1 | $1K | Sell |
13
-3
| -19% | -$209 | ﹤0.01% | 5961 |
|
|
2018
Q4 | $1K | Buy |
16
+1
| +7% | +$77 | ﹤0.01% | 6301 |
|
|
2018
Q3 | $1K | Buy |
15
+3
| +25% | +$207 | ﹤0.01% | 6316 |
|
|
2018
Q2 | $2K | Hold |
12
| – | – | ﹤0.01% | 6195 |
|
|
2018
Q1 | $2K | Sell |
12
-1
| -8% | -$285 | ﹤0.01% | 6209 |
|
|
2017
Q4 | $5K | Hold |
13
| – | – | ﹤0.01% | 6058 |
|
|
2017
Q3 | $7K | Sell |
13
-1
| -7% | -$660 | ﹤0.01% | 5954 |
|
|
2017
Q2 | $11K | Sell |
14
-2
| -13% | -$1.74K | ﹤0.01% | 5762 |
|
|
2017
Q1 | $14K | Buy |
16
+5
| +45% | +$8.28K | ﹤0.01% | 5790 |
|
|
2016
Q4 | $32K | Buy |
+11
| New | +$64K | ﹤0.01% | 5509 |
|
Other funds holding SLS
AFM
Wells Fargo's SLS Position: Q2 2026 in Review
Wells Fargo increased its SELLAS Life Sciences (SLS) stake by 46% in Q2 2026, buying an estimated $712K and bringing the position to 328,819 shares worth $4.85M. The position accounts for ﹤0.01% of the portfolio, ranked #2873.
Wells Fargo first reported a position in SLS in Q4 2016 and has held it in 35 quarters since. 193 funds tracked by Wall St. Rank hold SLS as of Q2 2026.
- Wells Fargo held 328,819 shares of SELLAS Life Sciences worth $4.85M as of Q2 2026.
- Wells Fargo bought 103,112 SELLAS Life Sciences shares in Q2 2026, an estimated $712K.
- SELLAS Life Sciences made up ﹤0.01% of Wells Fargo's portfolio in Q2 2026, its #2873 holding.
- Wells Fargo first reported a position in SELLAS Life Sciences in Q4 2016 and has held it in 35 quarters since.
- 193 funds tracked by Wall St. Rank held SELLAS Life Sciences as of Q2 2026.
Based on Wells Fargo's 13F filing for Q2 2026, filed 14 Aug 2026.